Patients interested in participating in stroke research studies can call our Neurology Clinical Research Coordinator, Diane Brown, RN, BSN, CCRP at (615) 936-0062.
The treatment of acute stroke is a recent, rapidly evolving area of research that has already delivered successful results. However, more needs to be done to further improve outcomes for patients. The Vanderbilt Stroke Center has been actively involved in research since 1992 and is currently managing these acute stroke trials:
SHINE: This study's goal is to to determine the efficacy of tight glucose control to a target range of 80-130 mg/dL with IV insulin infusion in hyperglycemic acute ischemic stroke patients within 12 hours of symptom onset as measured by mRS at 90 days after stroke.
TIME WINDOW: 0 – 12 hours
SOCRATES: This trial will compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by a 90 mg twice daily maintenance dose for the remainder of the study) vs. aspirin (300 mg [three 100 mg tablets] loading dose on Day 1 followed by a 100 mg once daily maintenance dose for the remainder of the study) for the prevention of major vascular events (composite of stroke, myocardial infarction [MI] and death) in patients with acute ischemic stroke or transient ischemic attack (TIA)
TIME WINDOW: 0 – 24 hours
GSK MAG: The primary goal of this study is to demonstrate a clinically meaningful improvement after treatment with GSK249320 in leg movement recovery, specifically by evaluating changes in walking speed from baseline to Day 90/Month 3 in subjects who have a measurable leg deficit and an impaired ability to walk at 24-72 hours post stroke.
TIME WINDOW: 24 – 72 hours
CLEAR III- Intraventricular Thrombolysis Clinical Trial: Intraventricular hemorrhage (IVH) is sudden bleeding into the ventricular system of the brain, often the result of intracerebral hemorrhage. This complication of hemorrhagic stroke has a mortality rate of 60-80% and only about 10% of patients recover with a good outcome.
CLEAR III is a 500-patient Phase-III randomized clinical trial using a recombinant tissue plasminogen activator (Activase) to quickly remove this blood from the ventricles. It is the hope of the over 70 academic medical centers in this international clinical trial that this may prove to be a better way to treat this brain injury.
POINT: Seeks to determine whether the blood-thinning drug clopidogrel (aka Plavix) is effective in preventing strokes, heart attacks and vascular death in patients who have had minor strokes.
Time Window: 0-12 hours
The prevention of stroke has been another success story. Primary stroke prevention with exercise, diet, smoking cessation and treatment of hypertension is important in all patients. Medical treatments to prevent stroke include combination anti-hypertensive medications, cholesterol management, carotid surgery, anticoagulation with warfarin for patients with cardiac sources of emboli to the brain, and antiplatelet therapy for patients with TIA or minor stroke.
There are several basic science (done in the laboratory) research projects ran and/or coordinated by Dr. McLaughlin, many sponsored by the NIH or the department of Defense, among them:
For information or scheduling for the BOLD study, contact:
Practice Manager, Interventional Neuroradiology
Fax: (615) 322-6889
Institute of Imaging Science
Also, with our Neurointerventional team, the Vanderbilt Stroke Center is involved in the application of angioplasty and stent placement in patients with TIA and stroke secondary to arterial stenosis in the carotid or vertebrobasilar vessels, especially those in which standard surgical techniques are not applicable.